Adverum Biotechnologies Reports New Interim Data from Cohorts 1 and 2 of OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD at Angiogenesis, Exudation, and Degeneration 2020

Brenda Snow
Authentic Patient Voice

Joey Cohen
Medication Adherence

Bud Bilanich
Success Coach

Frank Burrell
Scientific Storytelling

Matthew Durham
Omnidynamic Marketing

Paul Theisen
Patient Acquisition

Matt Turner
Patient Affordability

Daniel Sontupe
Market Access

David Linetsky
Point-of-Care Marketing

Amy Giles
Increasing Engagement

Stacey Gandler
Brand Nourishment

Suma Ramadas, PhD
Medical Affairs

Liz Kane
Impactful Strategy

Pat Purcell
Meeting Engagement